Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Michael Szarek

Concepts (315)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Acute Coronary Syndrome
39
2026
299
6.300
Why?
Anticholesteremic Agents
32
2026
156
5.460
Why?
Hydroxymethylglutaryl-CoA Reductase Inhibitors
43
2026
449
5.070
Why?
Antibodies, Monoclonal, Humanized
46
2026
992
4.200
Why?
Cholesterol, LDL
48
2026
363
3.540
Why?
Lipoprotein(a)
18
2026
70
3.120
Why?
Glycosides
13
2026
43
2.430
Why?
Peripheral Arterial Disease
16
2026
507
2.160
Why?
Cardiovascular Diseases
29
2026
2219
2.130
Why?
Heptanoic Acids
20
2014
67
1.590
Why?
Dyslipidemias
9
2025
184
1.540
Why?
Stroke
14
2022
1287
1.470
Why?
Pyrroles
20
2014
222
1.460
Why?
Myocardial Infarction
17
2024
1215
1.440
Why?
Diabetes Mellitus, Type 2
17
2026
2623
1.300
Why?
Ischemic Attack, Transient
4
2020
71
1.300
Why?
Proprotein Convertase 9
19
2026
88
1.280
Why?
Rivaroxaban
14
2026
270
1.260
Why?
Cholesterol Ester Transfer Proteins
6
2026
22
1.210
Why?
Treatment Outcome
63
2026
11821
1.200
Why?
Double-Blind Method
38
2026
2070
1.190
Why?
Platelet Aggregation Inhibitors
12
2026
499
1.130
Why?
Hyperlipoproteinemia Type II
5
2026
32
1.120
Why?
Eicosapentaenoic Acid
2
2025
37
1.020
Why?
Angina, Unstable
7
2019
83
0.930
Why?
Atherosclerosis
7
2026
410
0.910
Why?
Heart Failure
9
2026
2329
0.880
Why?
Brain Ischemia
7
2022
362
0.850
Why?
Hypertriglyceridemia
1
2024
45
0.800
Why?
Serine Proteinase Inhibitors
5
2025
48
0.800
Why?
Lower Extremity
10
2026
453
0.760
Why?
Factor Xa Inhibitors
8
2026
195
0.740
Why?
Aged
71
2026
26432
0.720
Why?
Antibodies, Monoclonal
6
2026
1512
0.720
Why?
Middle Aged
68
2026
36619
0.680
Why?
Humans
124
2026
146342
0.660
Why?
Renal Insufficiency, Chronic
6
2025
640
0.640
Why?
Aspirin
11
2026
405
0.630
Why?
Drug Therapy, Combination
14
2026
1036
0.620
Why?
Hypercholesterolemia
7
2020
95
0.590
Why?
Carcinoma, Renal Cell
1
2021
231
0.550
Why?
Male
82
2026
73396
0.550
Why?
Patient Admission
1
2019
216
0.520
Why?
Female
80
2026
79499
0.510
Why?
Simvastatin
4
2010
58
0.510
Why?
Kidney Neoplasms
1
2021
419
0.480
Why?
Risk Factors
21
2026
10921
0.450
Why?
Vascular Surgical Procedures
3
2026
352
0.450
Why?
Biomarkers
16
2026
4340
0.440
Why?
Endovascular Procedures
3
2026
390
0.410
Why?
Apolipoproteins B
8
2026
48
0.400
Why?
Patient Readmission
1
2019
778
0.400
Why?
Venous Thromboembolism
3
2023
332
0.380
Why?
Global Health
3
2021
403
0.380
Why?
Life Change Events
1
2014
144
0.380
Why?
RNA, Small Interfering
2
2026
633
0.380
Why?
Ischemia
5
2022
421
0.370
Why?
Triglycerides
3
2024
527
0.360
Why?
Secondary Prevention
5
2019
248
0.360
Why?
Career Choice
1
2014
237
0.350
Why?
Time Factors
12
2026
7109
0.340
Why?
Markov Chains
2
2010
129
0.340
Why?
Cholesterol, HDL
6
2025
201
0.340
Why?
Risk Assessment
9
2025
3712
0.320
Why?
Coronary Artery Bypass
2
2025
269
0.320
Why?
Phospholipids
3
2025
215
0.320
Why?
C-Reactive Protein
4
2026
429
0.310
Why?
Cholesterol
3
2022
411
0.310
Why?
Thrombosis
2
2025
398
0.300
Why?
Randomized Controlled Trials as Topic
7
2026
1763
0.290
Why?
Follow-Up Studies
9
2026
5439
0.290
Why?
Students, Medical
1
2014
383
0.290
Why?
Ezetimibe
2
2026
24
0.280
Why?
Coronary Disease
5
2009
380
0.280
Why?
Infectious Disease Transmission, Vertical
1
2010
188
0.280
Why?
Rosuvastatin Calcium
3
2026
21
0.270
Why?
Apolipoproteins
3
2025
38
0.260
Why?
Apolipoprotein B-100
2
2025
13
0.250
Why?
Albuminuria
3
2024
190
0.240
Why?
Lipoproteins, VLDL
1
2026
21
0.240
Why?
Receptors, Urokinase Plasminogen Activator
1
2026
15
0.240
Why?
Models, Statistical
1
2010
669
0.230
Why?
Receptors, LDL
1
2026
53
0.230
Why?
Hemorrhage
7
2026
825
0.230
Why?
Hyperlipoproteinemia Type III
1
2025
4
0.230
Why?
Proportional Hazards Models
9
2019
1331
0.230
Why?
Saphenous Vein
1
2025
36
0.220
Why?
Vascular Patency
1
2025
115
0.220
Why?
Graft Occlusion, Vascular
1
2025
39
0.220
Why?
Survival Analysis
1
2008
1378
0.210
Why?
tau Proteins
1
2025
111
0.210
Why?
HIV-1
1
2010
913
0.200
Why?
Interleukin-6
3
2026
784
0.200
Why?
Anticoagulants
4
2023
746
0.200
Why?
Glomerular Filtration Rate
2
2024
745
0.190
Why?
Primary Health Care
1
2014
1776
0.190
Why?
Internship and Residency
1
2014
1281
0.190
Why?
Fibrin Fibrinogen Degradation Products
1
2023
92
0.190
Why?
Hyperlipidemias
1
2003
120
0.180
Why?
Apolipoproteins E
2
2025
97
0.180
Why?
Antifibrinolytic Agents
1
2023
68
0.180
Why?
Muscles
1
2022
330
0.170
Why?
Blood Coagulation Disorders
1
2023
190
0.160
Why?
Hospitalization
6
2023
2475
0.160
Why?
Cataract
1
2023
240
0.160
Why?
Phenylurea Compounds
1
2021
122
0.160
Why?
Quinolines
1
2021
191
0.150
Why?
Kidney Diseases
1
2023
428
0.150
Why?
Renal Insufficiency
1
2021
173
0.150
Why?
Colonic Neoplasms
1
2021
259
0.140
Why?
Health Status
1
2024
827
0.140
Why?
Patient Care Team
1
2024
701
0.140
Why?
Liver X Receptors
1
2018
29
0.130
Why?
Multifactorial Inheritance
1
2019
243
0.130
Why?
Venous Thrombosis
1
2020
199
0.130
Why?
Diabetes Complications
1
2019
219
0.130
Why?
Dose-Response Relationship, Drug
6
2021
2022
0.130
Why?
Neoplasms, Experimental
1
2018
163
0.130
Why?
Cost-Benefit Analysis
1
2020
640
0.120
Why?
Lipids
4
2010
714
0.120
Why?
Myeloid-Derived Suppressor Cells
1
2018
78
0.120
Why?
Prospective Studies
8
2022
8123
0.120
Why?
Pyrans
2
2026
7
0.120
Why?
Diabetes Mellitus, Type 1
2
2023
3930
0.120
Why?
Myocardial Ischemia
3
2007
286
0.110
Why?
Atrial Fibrillation
1
2022
560
0.110
Why?
Adult
16
2026
41087
0.110
Why?
Heterozygote
2
2026
311
0.110
Why?
HIV Infections
1
2010
3215
0.110
Why?
Hospital Mortality
1
2019
1051
0.110
Why?
Proprotein Convertases
1
2014
16
0.110
Why?
Killer Cells, Natural
1
2018
481
0.100
Why?
Receptors, Interleukin-3
1
2014
5
0.100
Why?
Antigens, Neoplasm
2
2006
271
0.100
Why?
Neoplasm Recurrence, Local
1
2021
1160
0.100
Why?
Immunotherapy, Adoptive
1
2018
356
0.100
Why?
Hypoglycemic Agents
4
2024
1412
0.100
Why?
Disease-Free Survival
2
2018
778
0.100
Why?
Skin Neoplasms
2
2014
806
0.100
Why?
Colorectal Neoplasms
1
2021
874
0.100
Why?
Coronary Artery Disease
1
2019
751
0.090
Why?
Aged, 80 and over
8
2026
8391
0.090
Why?
Clinical Trials as Topic
3
2008
1064
0.090
Why?
Injections, Subcutaneous
2
2024
170
0.090
Why?
Hematologic Neoplasms
1
2014
170
0.090
Why?
Neoplasms
2
2023
2954
0.090
Why?
Developing Countries
1
2014
312
0.090
Why?
Immunity, Innate
1
2018
844
0.090
Why?
Clinical Decision-Making
1
2015
365
0.080
Why?
Recombinant Fusion Proteins
1
2014
663
0.080
Why?
Diabetes Mellitus
1
2020
1101
0.080
Why?
Heparin
2
2023
247
0.080
Why?
Sodium-Glucose Transporter 1
2
2020
11
0.080
Why?
Leukemia, Myeloid, Acute
1
2018
702
0.080
Why?
Urban Population
1
2014
497
0.080
Why?
Bottle Feeding
1
2010
19
0.080
Why?
Norway
1
2010
41
0.080
Why?
Stroke Volume
2
2024
652
0.080
Why?
Dendritic Cells
1
2014
509
0.080
Why?
Denmark
1
2010
51
0.080
Why?
Finland
1
2010
72
0.080
Why?
Netherlands
1
2010
85
0.080
Why?
Serum Amyloid A Protein
2
2007
32
0.080
Why?
Arteries
2
2022
261
0.080
Why?
Likelihood Functions
1
2010
138
0.080
Why?
Sweden
1
2010
114
0.080
Why?
Antineoplastic Agents
1
2021
2219
0.080
Why?
Risk
6
2008
920
0.080
Why?
Probability
1
2010
309
0.070
Why?
Myocardial Revascularization
1
2009
85
0.070
Why?
Statistics, Nonparametric
1
2010
426
0.070
Why?
Hydroxymethylglutaryl CoA Reductases
1
2009
13
0.070
Why?
Melanoma
2
2006
765
0.070
Why?
Biomarkers, Tumor
2
2006
1339
0.070
Why?
United States Government Agencies
1
2008
5
0.070
Why?
Practice Guidelines as Topic
3
2019
1591
0.070
Why?
Oxidation-Reduction
3
2025
1075
0.070
Why?
Biometry
1
2008
67
0.070
Why?
Inflammation
4
2023
2919
0.060
Why?
Tissue Plasminogen Activator
2
2022
245
0.060
Why?
Cell Line, Tumor
3
2021
3545
0.060
Why?
Counseling
1
2010
406
0.060
Why?
Recurrence
4
2019
1133
0.060
Why?
Incidence
3
2022
2936
0.060
Why?
Breast Feeding
1
2010
447
0.060
Why?
Postoperative Complications
1
2019
3034
0.060
Why?
Decision Making
1
2014
993
0.060
Why?
United States
3
2019
16136
0.060
Why?
Data Interpretation, Statistical
1
2008
368
0.060
Why?
Reactive Oxygen Species
1
2009
610
0.060
Why?
Fibrinolytic Agents
2
2022
303
0.060
Why?
Predictive Value of Tests
3
2025
2113
0.060
Why?
Dicarboxylic Acids
1
2025
12
0.060
Why?
Limb Salvage
1
2026
74
0.060
Why?
Acute Disease
3
2021
1038
0.060
Why?
Clinical Trials, Phase III as Topic
1
2025
116
0.060
Why?
Natriuretic Peptide, Brain
1
2026
110
0.060
Why?
Prognosis
4
2026
4351
0.050
Why?
Esters
1
2025
71
0.050
Why?
Cancer Vaccines
1
2006
161
0.050
Why?
Medication Adherence
1
2009
535
0.050
Why?
CD40 Ligand
1
2004
32
0.050
Why?
Lipoproteins, HDL
1
2005
104
0.050
Why?
Antigen-Antibody Complex
1
2004
70
0.050
Why?
Multicenter Studies as Topic
1
2026
417
0.050
Why?
Lipoproteins, LDL
1
2004
119
0.050
Why?
Subtilisins
1
2023
9
0.050
Why?
Thromboplastin
1
2023
67
0.050
Why?
Severity of Illness Index
2
2026
2921
0.050
Why?
Creatine Kinase
1
2022
70
0.040
Why?
Fatty Acids
1
2025
460
0.040
Why?
Numbers Needed To Treat
1
2021
7
0.040
Why?
Peptide Fragments
1
2026
693
0.040
Why?
Plasma Membrane Neurotransmitter Transport Proteins
1
2021
6
0.040
Why?
Pharmacogenomic Testing
1
2022
63
0.040
Why?
Metabolic Syndrome
1
2005
364
0.040
Why?
Inflammation Mediators
1
2004
508
0.040
Why?
Creatine
1
2021
63
0.040
Why?
Precision Medicine
1
2025
462
0.040
Why?
Receptors, Immunologic
1
2022
210
0.040
Why?
Goals
1
2022
187
0.040
Why?
Mice
3
2026
18297
0.040
Why?
Proto-Oncogene Proteins p21(ras)
1
2021
250
0.040
Why?
Membrane Transport Proteins
1
2021
154
0.040
Why?
Algorithms
1
2008
1849
0.040
Why?
Diabetic Nephropathies
1
2024
320
0.040
Why?
Disease Progression
2
2024
2867
0.040
Why?
Mycoses
1
2020
87
0.040
Why?
Placebo Effect
1
2019
23
0.040
Why?
Mice, Nude
1
2021
668
0.040
Why?
Ventricular Function, Left
1
2023
541
0.040
Why?
Odds Ratio
3
2009
1077
0.040
Why?
Hypotension
1
2020
125
0.040
Why?
Diarrhea
1
2020
190
0.040
Why?
Age Factors
1
2007
3347
0.040
Why?
Patient Education as Topic
1
2024
770
0.040
Why?
Antigens, CD
1
2022
560
0.040
Why?
Propensity Score
1
2021
376
0.030
Why?
Sex Characteristics
1
2024
801
0.030
Why?
Transplantation, Haploidentical
1
2018
23
0.030
Why?
Sex Factors
1
2024
2107
0.030
Why?
Diabetic Ketoacidosis
1
2020
212
0.030
Why?
Nerve Tissue Proteins
1
2021
597
0.030
Why?
American Heart Association
1
2019
364
0.030
Why?
Cell Count
1
2018
315
0.030
Why?
Mice, SCID
1
2018
360
0.030
Why?
Muscular Diseases
2
2008
110
0.030
Why?
Erythrocytes
1
2022
750
0.030
Why?
Cohort Studies
2
2022
6077
0.030
Why?
Vascular Diseases
1
2019
252
0.030
Why?
Morbidity
1
2017
319
0.030
Why?
Liver
1
2024
1864
0.030
Why?
Mice, Inbred NOD
1
2018
598
0.030
Why?
Infant
1
2010
10114
0.030
Why?
Kidney
1
2024
1498
0.030
Why?
Membrane Proteins
1
2022
1130
0.030
Why?
Immunoglobulin M
2
2009
284
0.030
Why?
Animals
3
2026
38107
0.030
Why?
Cytoplasm
2
2006
253
0.030
Why?
Genome-Wide Association Study
1
2022
1537
0.030
Why?
Cause of Death
1
2017
456
0.030
Why?
Tissue Donors
1
2018
425
0.030
Why?
Fluorobenzenes
1
2014
17
0.030
Why?
Xenograft Model Antitumor Assays
1
2018
930
0.030
Why?
Interleukin-3
1
2014
23
0.030
Why?
Syndrome
2
2007
380
0.030
Why?
Diphtheria Toxin
1
2014
61
0.030
Why?
Cell Proliferation
1
2021
2502
0.030
Why?
Thrombolytic Therapy
1
2015
165
0.020
Why?
Serine Endopeptidases
1
2014
129
0.020
Why?
Multivariate Analysis
2
2007
1543
0.020
Why?
Immunoglobulin G
2
2009
901
0.020
Why?
Acute Kidney Injury
1
2020
866
0.020
Why?
Quality of Life
1
2024
3200
0.020
Why?
Child, Preschool
2
2005
11913
0.020
Why?
Neoplasm Staging
2
2006
1488
0.020
Why?
CD8-Positive T-Lymphocytes
1
2018
931
0.020
Why?
Molecular Targeted Therapy
1
2014
447
0.020
Why?
Pyrimidines
1
2014
532
0.020
Why?
Adolescent
3
2006
22557
0.020
Why?
Mice, Knockout
1
2018
3125
0.020
Why?
Sulfonamides
1
2014
594
0.020
Why?
Mutation
1
2021
4093
0.020
Why?
Autoantibodies
2
2009
1500
0.020
Why?
Pilot Projects
1
2015
1888
0.020
Why?
Ireland
1
2008
33
0.020
Why?
Apolipoprotein A-I
1
2008
39
0.020
Why?
Europe
1
2009
421
0.020
Why?
Thromboembolism
1
2009
129
0.020
Why?
Lipoproteins
1
2009
165
0.020
Why?
United Kingdom
1
2008
377
0.020
Why?
Child
2
2005
22693
0.020
Why?
Drug Prescriptions
1
2009
314
0.020
Why?
Cerebral Infarction
1
2006
46
0.010
Why?
Gastrointestinal Diseases
1
2008
220
0.010
Why?
Hematuria
1
2005
11
0.010
Why?
Immunotherapy, Active
1
2005
9
0.010
Why?
ROC Curve
1
2007
617
0.010
Why?
Aspartate Aminotransferases
1
2005
86
0.010
Why?
Cerebral Hemorrhage
1
2006
125
0.010
Why?
Alanine Transaminase
1
2005
151
0.010
Why?
Drug Administration Schedule
1
2007
790
0.010
Why?
Drug Utilization
1
2005
171
0.010
Why?
Arteriosclerosis
1
2004
82
0.010
Why?
Chemical and Drug Induced Liver Injury
1
2005
138
0.010
Why?
Angina Pectoris
1
2004
76
0.010
Why?
Enzyme-Linked Immunosorbent Assay
1
2006
846
0.010
Why?
Solubility
1
2004
240
0.010
Why?
Troponin
1
2003
50
0.010
Why?
Research Design
1
2009
1143
0.010
Why?
Databases, Factual
1
2008
1493
0.010
Why?
Heart Arrest
1
2004
411
0.010
Why?
Pain
1
2005
790
0.010
Why?
Retrospective Studies
2
2007
17438
0.010
Why?
Brain
1
2007
2991
0.010
Why?
Szarek's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)